Immix Biopharma Investor Presentation Deck
IMX-110 MoA: Tissue-Specific Therapeutic™ with TME Normalization™ Technology
www.
wwwwww
-PEG-PE
-DOX
- CUR
●
www.
www.
www.
0
14-16nm diameter
wwwww
www.
IgG Antibody: 10-15nm diameter
BCL-X
BCL2
-my
urvivi
PI3K
AKT
IMX-110
Upregulation in Cancer
¡MX-110 Downregulation
O
O
O
O
NFKB
COX2
spase
O
Jak
TAT3
¡MX-110 DNA Damage
¡MX-110 Upregulation
X
IMX-110 is a negatively-charged Tissue-Specific Therapeutic™M built on our TME
Normalization™ Technology encapsulating a synergistic 5:1 ratio of
poly-kinase inhibitor (polyphenol curcuminoid complex, or PCC) and apoptosis
inducer (PEG-PE doxorubicin complex) delivered deep into the TME.
First Oncology Micelle to achieve "small molecule penetration"
Electrostatic charge attracts to tumor like a magnet
iMX-110
Disperses Throughout Cell
Resulting in 1,200% increase in apoptosis (tumor cell death) vs. conventional
therapies
m
(
Wil
IMX-110 - Key Characteristics
Get There: Deliver Payload Deep Into
the Tumor Microenvironment
Stay There: Accumulate in Tumors
Kill Tumors: 12x Tumor Killing vs SoC
1%
% of dose / g organ
Control
10.
(g)
8.
1
0
intensity (a.u.) →→→
600
15%
200
-200
-12nm
-60nm
-125nm
10 20 30 40 50
Time (h)
Free DOX
●●●
IMMIX
S BIOPHARMA
40
80
distance from vessel (um)->
(Adapted from Popovic et al, 2010)
Caspase 3/7 Increase (%) vs. Control (empty micelle) as an indicator of tumor apoptosis, after 24h
1,200% increase -181%
penetration depth
35%
Micellular DOX
DOX micelles
Free DOX
53%
CUR micelles
iMX-110
35
Source: Development and manufacturing of novel locally produced anti-BCMA CART cells for the treatment of relapsed/refractory multiple myeloma: phase I clinical results. Haematologica. 2022 Oct 6. doi: 10.3324/haematol. 2022.281628. Epub ahead of print. PMID: 36200421. Stan, S. D. et al. Nat. Rev. Gastroenterol. Hepatol. 7, 347-356
(2010); published online 4 May 2010. http://www.nature.com/doifinder/10.1038/nrgastro.2010.61. Popovic et al, A nanoparticle size series for in vivo fluorescence imaging. Angew Chem Int Ed Engl. 2010 Nov 8; 49(46): 8649-8652. https://dx.doi.org/10.1002%2Fanie.201003142; M Yokoyama, T Okano, Y Sakurai, S Fukushima, K Okamoto, K
Kataoka. Selective delivery of adriamycin to a solid tumor using a polymeric micelle carrier system. https://doi.org/10.3109/10611869909085500; Sarisozen et. al. (2016- https://doi.org/10.1016/j.ejpb.2016.08.013).View entire presentation